




PHARMACEUTICAL 2020

Hepion Pharmaceuticals Inc.
Rank 126 of 362





RealRate

PHARMACEUTICAL 2020

Hepion Pharmaceuticals Inc.
Rank 126 of 362

The relative strengths and weaknesses of Hepion Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hepion Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Hepion Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is -77%, being 226% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	14,389
Cost of Goods Sold	0
Intangible Assets	1,871
Liabilities, Current	1,252
Liabilities, Non-Current	541
Other Assets	4,116
Other Compr. Net Income	0
Other Expenses	-672
Other Liabilities	2,454
Other Net Income	379
Property and Equipment	57
Research and Development	3,184
Revenues	0
Selling, General and Administrative Expense	4,586

Output Variable	Value in 1000 USD
Assets	20,433
Liabilities	4,247
Expenses	7,098
Stockholders Equity	16,186
Net Income	-6,719
Comprehensive Net Income	-6,719
Economic Capital Ratio	-77%



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai